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Abstract
This survey analyzes two national pharmacovigilance databases in order to determine the
major adverse reactions observed with the use of cholinesterase inhibitors in dementia. We
conducted a statistical analysis of the Food and Drug Administration Adverse Event Report-
ing System (FAERS) and the Canada Vigilance Adverse Reaction Database (CVARD) con-
cerning the side effects of cholinesterase inhibitors. The statistics calculated for each
adverse event were the frequency and the reporting odds ratios (ROR). A total of 9877 and
2247 reports were extracted from the FAERS and CVARD databases, respectively. A dis-
proportionately higher frequency of reports of death as an adverse event for rivastigmine,
compared to the other acetylcholinesterase inhibiting drugs, was observed in both the
FAERS (ROR = 3.42; CI95% = 2.94–3.98; P<0.0001) and CVARD (ROR = 3.67; CI95% =
1.92–7.00; P = 0.001) databases. While cholinesterase inhibitors remain to be an important
therapeutic tool against Alzheimer’s disease, the disproportionate prevalence of fatal out-
comes with rivastigmine compared with alternatives should be taken into consideration.
Introduction
This study aims to analyze the Food and Drug Administration Adverse Event Reporting Sys-
tem (FAERS) [1] database and the Canada Vigilance Adverse Reaction Database (CVARD)
[2], to determine the relative frequencies of adverse events reported during the post-marketing
monitoring of cholinesterase inhibitors used in the treatment of dementia.
Dementia has been described as a progressive impairment of cognitive and intellectual fac-
ulties caused by disorders affecting the brain [3]. Among the causes of dementia, Alzheimer’s
disease (AD) is the most common, representing 60–80% of cases [4]. Over 35 million people
suffer from Dementia worldwide, with 7.7 million new cases diagnosed each year, [5] and due
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to the global aging of populations, it has been estimated that the number of people affected by
dementia will reach around 115 million by 2050 [6][7]. The rates of increase are not uniform
from one country to another and they are projected to increase by 300% in developing coun-
tries while 100% in developed countries, making dementia and AD an international challenge
for the future [8][9].
The current treatment options for AD are focused on the alleviation of symptoms and
extending patient autonomy. Among the treatments, the cholinesterase inhibitor class are used
for mild to moderate Alzheimer’s disease and related dementia. Several controlled clinical trials
based on a specially selected population have tested these three drugs and showed them to be
of comparable efficacy and safety [10][11][12]. However, due to the limited population tested
in clinical trials, some rare adverse reactions may not surface until an extensive body of post-
marketing data is accumulated. Since the cholinesterase inhibitors were introduced for treat-
ment of Alzheimer’s disease, thousands of adverse event reports have been submitted to the
FAERS and CVARD databases.
The post-marketing monitoring has proved its usefulness in revealing serious adverse effects
missed in clinical trials and many drugs have been either removed from the market or have
seen warnings added to their labels due to post marketing reports of previously unknown or
insufficiently quantified serious adverse events (CDER 2005 Report to The Nation, 2005).
Some examples include Tetrazepam [13], a benzodiazepine derivative with anxiolytic and mus-
cle relaxant properties that has been removed from the European market in July 2013 because
of rare but serious life-threatening skin reactions. However, the duration of time that drugs are
on the market prior to their removal varied widely. For example, temafloxacin (Omniflox) was
removed after 4 months, whereas propoxyphene (Darvocet) was not removed until 55 years
after it was approved. Discrepancies like these indicate that a timely analysis of post-marketing
data is critical for drug safety.
In 2010, Novartis and the FDA highlighted the fact that Healthcare Professionals and Care-
givers had to be careful about the proper use and application of Exelon1 Patch (rivastigmine
transdermal system). Indeed, due to several errors of medication with the patch form, serious
adverse events that have required hospitalization and sometimes led to death have been
reported [14].
To better understand these observations, we first focused our work on the adverse events of
cholinesterase inhibitors reported to the FDA Adverse Event Reporting System (FEARS) data-
base using a searching tool that significantly speeds and helps organize the data (Early Drug
Alert™, developed by Abagyan Lab at UCSD) [15]. Secondly, reports from the Canada Vigilance
Adverse Reaction Database were analyzed with a manual searching method, in order to com-
pare the results from the FDA FEARS with another large-scale patient population.
Methods
This study is a retrospective data analysis of adverse event reports based on the FDA Adverse
Event Reporting System Database (FAERS) and the Canada Vigilance Adverse Reaction Data-
base (CVARD). The disease classification used for both US and Canadian databases is based
on the MedDRA classification. Only reports with drug codes of “Primary Suspect” or “Second-
ary Suspect” from the FAERS database were included in our analysis, all other drug codes were
ignored.
FDA adverse event reporting system
FAERS, created in 2004, is a database containing adverse event and medication error reports
sent to the FDA. The reports of adverse event and medication error are voluntarily reported by
Adverse Effects of Cholinesterase Inhibitors in Dementia
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healthcare professionals and consumers to the FDA, either directly via MedWatch or indirectly
via drug manufacturers [16]. Clinical reviewers in the Center for Drug Evaluation and Research
(CDER) and the Center for Biologics Evaluation and Research (CBER) use this database to
monitor the safety of drugs after the FDA approval. However, FAERS is a public database and
the FDA provides data files upon request [17]. The data analyzed in this study are the reports
from the 2004 Q1 data to the 2012 Q3 data for the 3 FDA approved acetylcholinesterase inhibi-
tors: rivastigmine, donepezil and galantamine. The data from FAERS was organized into a
rational searchable interface by the Abagyan Lab at the UCSD Skaggs School of Pharmacy, and
subsequently named “Early Drug Alert” [15]. This resource presents a special analysis of the
primary data in which the adverse effects and indications are grouped into categories; and base-
line frequencies of adverse effects for comparison between different drugs with the same indi-
cation are calculated together with their variations.
Canada Vigilance Adverse Reaction Database
The Canadian Vigilance Adverse reaction database, created in 1965, contains reports submitted
by health professionals, consumers, manufacturers and distributors. Seven Canadian Vigilance
Regional offices collect reports and the Canada Vigilance Program supervises the whole data-
base. The Canada Vigilance Program uses this database to monitor the safety of drugs once
they are marketed. The data are accessible to public and can be extracted from their online plat-
form [18][19]. In this study, we extracted all the reports available in CVARD for rivastigmine,
donepezil and galantamine occurring between January 1st 1990 to January 1st 2014.
Statistical Analysis
Both FAERS and CVARD data were analyzed the same way. The statistics calculated were the
frequencies of the most highly reported adverse effects of rivastigmine, donepezil, galantamine
and the acetylcholinesterase inhibitor (AChEI) class (which includes reports from all three
AChEI’s). The FAERS database reports death, sudden death, sudden cardiac death, cardiac
death, brain death, accidental death and apparent death as different adverse events, while
the CVARD indicates the term ‘death’ for any fatal outcome. In order to compare the two dif-
ferent databases, we regrouped all the fatal outcomes from FAERS database into a single term,
“death”. The reports citing drug combinations were excluded to simplify the statistical analysis
of primary suspects and secondary suspect.
The relative odds of a particular AChEI having a particular adverse event report in compari-
son to its drug class as a whole were expressed as Reporting Odds Ratios (ROR) with 95% con-
fidence intervals (CI) and were calculated and using MedCalc1 software (version 15.2) [20]
[21]. Among four widely used data mining algorithms, ROR showed the best performance for
pharmacovigilance surveys [22][23]. Indeed, ROR is generally used to evaluate disproportion
in reporting AEs for a drug in comparison with all other drugs and it has been very useful for
many pharmacovigilance studies [24]. It allows an estimation of relative signal, giving a general
idea of how much more frequently a particular AE is associated with a drug in comparison to
other comparable drugs for the same indication.
It is important to note that the FAERS and CVARD do not allow for the derivation of the
absolute adverse effect frequencies because the reporting is voluntary and the total number of
prescriptions is not known. In the analysis below, the baselines used for the following rates and
frequencies calculated correspond to the total number of adverse effects reported. This is why
the rates and frequencies calculated are considered as relative because it does not reflect the fre-
quency or rates of a specific adverse effect for the acetylcholinesterase inhibitor users, but only
for users who made a report of an adverse event.
Adverse Effects of Cholinesterase Inhibitors in Dementia
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Results
FAERS Database
FAERS database included a total of 3661205 reports from January 2004 to January 2012. It con-
tains 9877 reports of side effects for rivastigmine, donepezil and galantamine. Rivastigmine
had the highest number of reports with 5918 reports, while donepezil and galantamine had
respectively 2221 and 1738 reports (Table 1).
The association between the use of AChEI and serious side effects is shown in Table 2.
Reporting odds ratios of Table 2 compare the rates of serious adverse events in specific drug to
the rates for the general AChEI drug class. Overall, death was more often reported in patients
using rivastigmine (ROR = 3.42; CI95% = 2.94–3.98; P<0.0001) and rhabdomylosis was more
often reported in patients using donepezil (ROR = 11; CI95% = 10.39–27.41; P<0.0001) in the
FAERS database. Fig 1 shows the reporting odds ratios (ROR) comparing the rates of death in
specific AChEI to the rates for the general AChEI drug class.
Canada Vigilance Adverse Reaction Database
In January 2014, The Canadian Vigilance Adverse reaction database included a total of 2247
reports for the AChEI drug class: 1396 reports for rivastigmine, 602 reports for donepezil and
249 reports for galantamine.
ROR in Table 3 compares the rates of death in specific AChEI to the rates for the general
AChEI drug class in the Canada Vigilance Adverse Reaction database. Death was more often
reported in patients using rivastigmine (ROR = 3.67; CI95% = 1.92–7.00; P = 0.001) than done-
pezil or galantamine. Fig 2 shows a histogram representation of the reporting odds ratios com-
paring the rates of death in specific AChEI to the rates for the general AChEI drug class.
Discussion
These results are subject to an underreporting bias limitation. Indeed, neither the total number
of prescription of cholinesterase inhibitors nor the relative numbers of prescriptions for rivas-
tigmine, donepezil and galantamine within the cholinesterase inhibitors group are known
because these data are not made available to the public by FAERS or CVARD. Moreover, all
reports used from the FAERS and CVARD are voluntary and doesn’t represent the totality of
adverse events induced by cholinesterase inhibitors. Thus, the results obtained are considered
relative because data used are not based on the total of cholinesterase inhibitor prescriptions
but on the total number of voluntary adverse events reports.
According to the results from the FAERS database Reporting Odds Ratios (Table 2),
p values for death reports indicate significant results for all cholinesterase inhibitors (p value
< 0.0001). Regarding the relative odds ratios, death was more often reported in patients
using rivastigmine (ROR = 3.42; CI95% = 2.94–3.98; P<0.0001) than for patients using done-
pezil (ROR = 0.26; CI95% = 0.21–0.32; P<0.0001) and galantamine (ROR = 0.51; CI95% =
0.42–0.61; P<0.0001). Furthermore, the Canadian Vigilance Adverse Reaction Database con-
firms this observation with patients using rivastigmine (ROR = 3.67; CI95% = 1.92–7.00;
P = 0.0001) (Table 3).
Although we need to take into account that the increased death reports with rivastigmine
might be influenced by the fact that rivastigmine is more often prescribed for patients with an
advanced stage of Alzheimer’s Disease, other hypotheses can be made. In order to further
investigate the underlying cause of our findings, we first determined what sets rivastigmine
apart from the other AChEIs. The most glaring difference between rivastigmine and the other
AChEIs is that rivastigmine is the only drug among the cholinesterase inhibitors to have the
Adverse Effects of Cholinesterase Inhibitors in Dementia
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transdermal patch administration form. [25]. It has been reported that improper use of the
transdermal administration form may lead to higher than recommended administered doses.
[26]. As explained in Novartis’ warning letter from the FDA in 2007 [14], a majority of medica-
tion errors have involved not removing the old patch prior to applying a new one, leading to
the application of multiple patches at one time. Indeed, a 2012 report from Henrik Lövborg,
Anna K Jönsson and Staffan Hägg [26] illustrates a patient’s fatal outcome involving a rivastig-
mine overdose due to a medication error with the patch form. The patient described in the
study was an 87-year-old male with dementia. He developed nausea, vomiting and renal failure
with disturbed electrolytes resulting in death. These events occurred after six rivastigmine
patches had concomitantly and erroneously been applied by health care personnel on two con-
secutive days.
Table 1. Top adverse effects for cholinesterase inhibitors in FAERS database.
Top Adverse Effects Drug specific reports AChEI class reports Specific drug frequency (%) AChEI class frequency (%)
rivastigmine– 5918 total reports
Death 995 1216 16.81 12.31
Vomiting 472 690 7.98 6.99
Fall 417 638 7.05 6.46
Nausea 374 557 6.32 5.64
Confusional State 361 475 6.10 4.81
Dizziness 256 381 4.33 3.86
Pneumonia 253 373 4.28 3.78
Diarrhoea 245 375 4.14 3.80
Hallucination 224 305 3.79 3.09
Malaise 219 304 3.70 3.08
donepezil– 2221 total reports
Bradycardia 178 338 8.01 3.42
Fall 139 638 6.26 6.46
Vomiting 122 690 5.49 6.99
Syncope 118 343 5.31 3.47
Convulsion 99 240 4.46 2.43
Nausea 99 557 4.46 5.64
Death 95 1216 4.28 12.31
Electrocardiogram QT prolonged 94 130 4.23 1.32
Rhabdomyolysis 94 114 4.23 1.15
Drug Interaction 86 183 3.87 1.85
galantamine– 1738 total reports
Death 126 1216 7.25 12.31
Vomiting 96 690 5.52 6.99
Nausea 84 557 4.83 5.64
Fall 82 638 4.72 6.46
Medication Error 71 102 4.09 1.03
Decreased Appetite 64 304 3.68 3.08
Loss of consciousness 61 248 3.51 2.51
Dizziness 59 381 3.39 3.86
Bradycardia 57 338 3.28 3.42
Confusional State 56 475 3.22 4.81
doi:10.1371/journal.pone.0144337.t001
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Table 2. FAERS database analysis of reported serious adverse effect.
Adverse Effect Cases ROR (95% CI) p value
rivastigmine
Death 995 3.42 (2.94–3.98) <0.0001
Fall 417 1.28 (1.08–1.52) 0.0038
Pneumonia 253 1.43 (1.15–1.78) 0.0016
Syncope 175 0.69 (0.55–0.85) 0.0007
Loss of Consciousness 128 0.71 (0.55–0.91) 0.0071
Convulsion 106 0.52 (0.40–0.67) <0.0001
Rhabdomyolysis 11 0.07 (0.04–0.13) <0.0001
donepezil
Death 95 0.26 (0.21–0.32) <0.0001
Fall 139 0.96 (0.79–1.16) 0.6616
Pneumonia 70 0.79 (0.61–1.03) 0.0800
Syncope 118 1.87 (1.49–2.34) <0.0001
Loss of Consciousness 59 1.08 (0.80–1.45) 0.6185
Convulsion 99 2.49 (1.91–3.23) <0.0001
Rhabdomyolysis 94 16.87 (10.39–27.41) <0.0001
galantamine
Death 126 0.51 (0.42–0.61) <0.0001
Fall 82 0.68 (0.53–0.86) 0.0012
Pneumonia 50 0.72 (0.53–0.97) 0.0309
Syncope 50 0.79 (0.59–1.08) 0.1358
Loss of Consciousness 61 1.55 (1.15–2.08) 0.0036
Convulsion 35 0.80 (0.55–1.14) 0.2156
Rhabdomyolysis 9 0.40 (0.20–0.79) 0.0082
doi:10.1371/journal.pone.0144337.t002
Fig 1. Rates of death for specific ChEI in the FAERS database.Reporting odds ratios comparing the rates of death for specific ChEI to the rates for the
general ChEI drug class.
doi:10.1371/journal.pone.0144337.g001
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Another difference between rivastigmine compared with the other cholinesterase inhibitors
relates to the molecular mechanism of action of these drugs. The acetylcholinesterase inhibitors
are thought to act via the inhibition of the catabolic acetylcholinesterase enzyme, leading to
increased acetylcholine availability at the synaptic cleft of cholinergic neurons. [27]. Although
the mechanism of action of these three drugs is common, there are pharmacological differences
that must be taken into account because of the possible repercussions on the tolerance. Both
donepezil and galantamine are reversible inhibitors of acetylcholinesterase, with a non-cova-
lent binding to the enzyme [28][29]. Rivastigmine, on the other hand, has been classified as an
intermediate-acting agent (pseudo-irreversible) [30]. However, a study on the kinetic and
structural interaction of rivastigmine with the acetylcholinesterase enzyme has shown that riv-
astigmine led to an extremely low reactivation of the acetylcholinesterase enzyme [31]. The
very tight bond observed between rivastigmine and the acetylcholinesterase enzyme active site
appeared to be almost irreversible and could potentially lead to an unexpected increase in the
duration of action.
Regarding other adverse effects uncovered during this study, donepezil was predominantly
associated with muscle related adverse effects. The reporting odds ratios from FAERS(Table 2)
indicate that donepezil is highly associated with reports of rhabdomyolysis in comparison to
Table 3. Analysis of death reports in the Canada Vigilance Adverse Reaction database.
Drug name Cases ROR Death (95% CI) P-value
Rivastigmine 64 3.67 (1.92–7.00) 0.0001
Donepezil 6 0.23 (0.10–0.54) 0.0006
Galantamine 5 0.57 (0.23–1.43) 0.2317
doi:10.1371/journal.pone.0144337.t003
Fig 2. Rates of death for specific ChEI in the Canada Vigilance Adverse Reaction database.Reporting odds ratios comparing the rates of death for
specific ChEI to the rates for the general ChEI drug class.
doi:10.1371/journal.pone.0144337.g002
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other AChEIs (ROR = 16.87; CI95% = 10.39–27.41; P<0.0001). In support of our findings, a
recent case report concluded that an acute renal failure secondary to rhabdomyolysis was prob-
ably induced by donepezil [32]. In this case an 84-year-old male patient with Alzheimer’s dis-
ease who had been taking donepezil 5mg daily for two months was admitted to the emergency
department for apathy, loss of cooperation and decreased muscle strength. Initially, the
patient’s kidney function indicated an acute renal failure, and donepezil was discontinued.
After discontinuation of donepezil, the patient’s renal function improved gradually until
becoming normal again after 12 days of care. According to author suggestions, the acute renal
failure was not a direct effect but may have been mediated by the necrotic myolytic effect of
donepezil.
The results obtained from both FAERS and CVARD were statistically significant and con-
sistent across both databases, in addition to being supported by case reports from clinicians. It
would have been even more reassuring to consider other national sources of pharmacovigi-
lance, however the differences in reporting policies, data accessibility, data access cost, data for-
mats and the absence of uniform vocabulary made further analysis difficult.
In conclusion, acetylcholinesterase inhibitors are efficient symptomatic treatments against
dementia, however we need to consider the risk profiles of each of these drugs so that the safest
drug can be chosen for each patient. The data from this study indicate an association between
rivastigmine and rare events of fatal outcomes, as well as donepezil and rhabdomyolysis. We
hope that these findings will help healthcare professionals to make more informed decisions
for their dementia patients.
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